1. |
Office of National Statistics. Cancer Statistics Registrations, England. Series MB1 no.41 London: Office for National Statistics, 2010.
|
2. |
Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 2010, 65(Suppl 2): ii32-ii40.
|
3. |
American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med, 2000, 162(5):1987-2001.
|
4. |
Hooper C, LeeYC, Maskell N, et al. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 2010, 65(Suppl 2): ii4-ii17.
|
5. |
Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology, 2015, 20(4): 654-659.
|
6. |
Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res, 1997, 3(1): 47-50.
|
7. |
Morgensztern D, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol, 2012, 7(10): 1485-1489.
|
8. |
William J, Lin HY, Lee J, et al. Revisiting stage ⅢB and Ⅳ non-small cell lung cancer analysis of the surveillance, epidemiology, and end results data. Chest, 2009, 136(3): 701-709.
|
9. |
Naito T, Satoh H, Ishikawa H, et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res, 1997, 17(6D): 4743-4746.
|
10. |
Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J, 1997, 10(8): 1907-1913.
|
11. |
Ryu JS, Ryu HJ, Lee SN, et al. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol, 2014, 32(9): 960-967.
|
12. |
Williams CD, Stechuchak KM, Zullig LL, et al. Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer. J Clin Oncol, 2013, 31(4): 475-481.
|
13. |
National Comprehensive Cancer Network. Non-small cell lung cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2004, 2(2): 94-123.
|
14. |
Xu CH, Yu LK, Zhan P, et al. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients. Eur J Med Res, 2014, 19(1): 1-6.
|
15. |
Thomas R, Francis R, Davies HE, et al. Interventional therapies for malignant pleural effusions: the present and the future. Respirology, 2014, 19(6): 809-822.
|
16. |
Sterman DH, Haas A, Moon E, et al. A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med, 2011, 184(12): 1395-1399.
|
17. |
Sterman DH, Recio A, Haas AR, et al. A phaseⅠtrial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther, 2010, 18(4): 852-860.
|